

Special Issue

Immune Responses to COVID-19 Vaccines

Message from the Guest Editor

Special Issue includes but is not restricted to the following:

- Use, efficacy, and safety of COVID-19 vaccines in frail persons such as, but not limited to, patients with cardiopulmonary chronic diseases, COPD, Diabetes, chronic renal failure, renal transplant carriers, and oncological/onco-hematological patients; in extreme ages (elderly/newborn), in pregnancy, in patients with chronic viral infections (HIV, HBV, or HCV), primary or secondary immune depression, or suffering for immune, allergic, or autoimmune diseases, either in treatment with immune modifying drugs or not
- Impact of COVID-19 vaccines in hospitalized/institutionalized persons and personnel and in special communities
- Off label use of COVID-19 vaccines: heterologous or mixed primer-booster schedules, extended prime to boost interval
- Interaction between COVID-19 vaccines and other vaccinations in newborns, in frail newborns (to an HIV/HBV/HCV-positive mother), in elderly, in multiple exposed frail patients
- Use and development of COVID-19 vaccines in medium–low-income countries or communities
- Next generation, new formulation, and new conception of COVID-19 vaccines.

Guest Editor

Dr. Federico De Marco

Department of RDAT, the Regina Elena National Cancer Institute IRCCS, Via Elio Chianesi 53, 00144 Rome, Italy

Deadline for manuscript submissions

closed (31 January 2023)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/112229

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).